UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/564,184	08/07/2006	Hans-Peter Buchstaller	24945-0028US	8024
Baker & Daniels LLP 805 15th Street NW Suite 700 Washington, DC 20005			EXAMINER	
			LOEWE, SUN JAE Y	
			ART UNIT	PAPER NUMBER
			1626	
			MAIL DATE	DELIVERY MODE
			05/05/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
Office Action Occurrence	10/564,184	BUCHSTALLER ET AL.				
Office Action Summary	Examiner	Art Unit				
	SUN JAE Y. LOEWE	1626				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 6(a). In no event, however, may a reply be timil apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1)⊠ Responsive to communication(s) filed on <u>25 Ja</u>	nuary 2008					
• • • • • • • • • • • • • • • • • • • •	action is non-final.					
3) Since this application is in condition for allowan		secution as to the merits is				
closed in accordance with the practice under E						
Disposition of Claims						
4)⊠ Claim(s) <u>1,3,5-13 and 15-33</u> is/are pending in t	he application.					
4a) Of the above claim(s) <u>12,13 and 15-31</u> is/ar						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1,3,5-11,32 and 33</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or	election requirement.					
Application Papers						
9)☐ The specification is objected to by the Examine						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Ex		• •				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign	priority under 25 LLS C & 110(a)	(d) or (f)				
a) ☐ All b) ☐ Some * c) ☐ None of:	priority under 35 0.5.6. § 119(a)	-(u) or (i).				
·— ·—	s have been received					
1. Certified copies of the priority documents		on No				
2. Certified copies of the priority documents						
3. Copies of the certified copies of the prior	*	d in this National Stage				
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachmont/c\						
Attachment(s) 1) Notice of References Cited (PTO-892)	4) Interview Summary	(PTO-413)				
2) Notice of Traftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	nte				
3) 🗖 Information Disclosure Statement(s) (PTO/SB/08)	5) Notice of Informal P	atent Application				
Paper No(s)/Mail Date <u>1-25-2008</u> .	6) [] Other:					

Art Unit: 1626

DETAILED ACTION

1. Claims 1, 3, 5-13 and 15-33 are pending in the instant application. Claims 2, 4 and 14 were cancelled by amendment filed on January 25, 2008.

Response to Amendment

2. The amendments to the claims filed on January 25, 2008 were fully considered. The following grounds of rejection are <u>withdrawn</u>: 35 USC 112 2nd paragraph; 35 USC 102. The amendments do not overcome the 35 USC 112 1st paragraph (written description and enablement) rejections.

Response to Arguments

3. Applicant's remarks filed on January 25, 2008 have been fully considered. However, they are not persuasive in overcoming the 35 USC 112 1st paragraph rejections (written description and enablement). Therefore, these grounds of rejection are <u>maintained</u> and hereby made FINAL. See response to arguments below, Sections 5 and 6.

Claim Objections

4. Claims 1, 3, 5-11, 32 and 33 objected to for containing non-elected subject matter.

Currently, examination is restricted to the elected species of

Art Unit: 1626

elected subject matter: compounds of formula I that are not the species denoted above.

Applicant is respectfully directed to the restriction requirement dated July 25, 2007, excerpts below:

•• Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141.

Claim Rejections - 35 USC § 112

(Written Description)

5. Below are responses to Applicant's remarks:

"The specification provides the skilled artison
 with ample chemical structure information to immediately envision chemical species
 commensurate with the scope of the claimed genera of the rejected claims.

Applicant's remarks do not provide for the <u>disclosure</u> of additional <u>species</u> in support of the claimed genus. It is maintained that the species disclosed are limited to those denoted in the previous office action (pg. 6-7, section entitled "Scope of Disclosure").

b) "Furthermore, the Examinar asserts that disclusion of species supporting the claimed genera is limited to compounds actually reduced to practice. However, written description may be satisfied by the description of a representative number of species. Actual reduction to practice of species is not required.

Applicant's comment is noted. Actual reduction to practice is one of several ways that Applicant may disclose species in support of a claimed genus. Applicant is invited to point out where in the instant specification there is disclosure of <u>species</u> additional to those reduced to practice. Presently, in view of the reasons

Application/Control Number: 10/564,184

Art Unit: 1626

presented in the previous office action (pg. 6-7, "Scope of Disclosure"), it is maintained that the scope of the disclosure is limited to the species reduced to practice.

It is maintained that 35 USC 112 1st paragraph (written description) rejection was proper.

Thus, this ground of rejection is maintained and hereby made FINAL.

(Enablement)

- 6. Below are responses to Applicant's remarks:
 - "Applicants would like to submit
 that the Examiner is required to state what claim embadiments are enabled in the specification.

The Examiner has stated that the specification is coabling for the use of compounds that have adequate written description. Applicants, respectfully request that the Examiner charify what

he maintains are enabled claim embodiments.

The enabled claim embodiments are compounds of Formula I encompassed by the genus defined by:

```
R<sup>6</sup>M<sup>7</sup>: hydrogen or unsubstituted alkyl, halosikyl, halogen

R<sup>8</sup>M<sup>9</sup>: hydrogen, unsubstituted alkyl, halosikyl, halogen

R<sup>19</sup>: hydrogen, unsubstituted alkyl, halosikyl, halogen

**Constant **Con
```

(see office action, pg. 7, pg. 8). Furthermore, it is suggested for Applicant to delete the intended use language in claims 7 and 8 to overcome this ground of rejection.

b) "Applicants
respectfully request reconsideration and withdrawal of the enablement rejection because
determining the activity of the species falling within the claimed genera for Raf Kinase
inhibition would not require undue experimentation as numerous require methodologies are
available to the skilled artisan to assess such activity
"

The suggestion to experiment (ie. test instantly claimed compounds to see if they inhibit Raf kinase) is deemed not to fulfill the requirements set forth by 35 USC

Art Unit: 1626

112 1st paragraph. Applicant is respectfully referred to MPEP 2164.03, excerpts below:

"The scope of the required enablement varies inversely with the degree of predictability involved, but even in unpredictable arts, a disclosure of every operable species is not required. A single embodiment may provide broad enablement in cases involving predictable factors, such as mechanical or electrical elements. In re Vickers, 141 F.2d 522, 526-27, 61 USPQ 122, 127 (CCPA 1944); In re Cook, 439 F.2d 730, 734, 169 USPQ 298, 301 (CCPA 1971). However, in applications directed to inventions in arts where the results are unpredictable, the disclosure of a single species usually does not provide an adequate basis to support generic claims. In re Soll, 97 F.2d 623, 624, 38 USPQ 189, 191 (CCPA 1938). In cases involving unpredictable factors, such as most chemical reactions and physiological activity, more may be required. In re Fisher, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970) (contrasting mechanical and electrical elements with chemical reactions and physiological activity). See also In m Wright, 999 F.2d 1557, 1562, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993); In re Vaeck, 947 F.2d 488, 496, 20 USPQ2d 1438, 1445 (Fed. Cir. 1991). This is because it is not obvious from the disclosure of one species, what other species will work. "

Conclusion

7. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37

Art Unit: 1626

CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event,

however, will the statutory period for reply expire later than SIX MONTHS from the mailing

date of this final action.

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to SUN JAE Y. LOEWE whose telephone number is (571)272-

9074. The examiner can normally be reached on M-F 7:30-5:00 Est.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Joseph McKane can be reached on (571)272-0699. The fax phone number for the

organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would

like assistance from a USPTO Customer Service Representative or access to the automated

information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Sun Jae Y. Loewe, Ph.D./

4-30-2008

/Kamal A Saeed, Ph.D./ Primary Examiner, Art Unit 1626